


Anticancer agent 201

Cat. No.:	HY-163435
Molecular Formula:	C ₃₄ H ₄₉ F ₃ O ₄
Molecular Weight:	578.75
Target:	Apoptosis; Caspase; PARP; Bcl-2 Family
Pathway:	Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 201 (Compound 2f) has IC ₅₀ values in the low micromolar range for multiple tumor cell lines. Anticancer agent 201 is highly cytotoxic to CCRF-CEM cells in vitro, inducing apoptosis by activating caspase-3 in the intrinsic mitochondrial pathway and lysis of PARP, as well as reducing the expression of Bcl-2 and Bcl-XL proteins. Anticancer agent 201 can be used in cancer research ^[1] .																																							
IC₅₀ & Target	Caspase-3	Bcl-2			Bcl-xL																																			
In Vitro	<p>Anticancer agent 201 (Compound 2f) (3.5 μM, 17.5 μM; 24h) significantly induces cytotoxic reactions, increases the number of apoptotic cells, and leads to a dose-dependent reduction of mitochondrial membrane potential in CCRF-CEM cells^[1]. Anticancer agent 201 (3.5 μM, 17.5 μM; 24h) blocks or slows down the G0/G1 phase cell cycle in CCRF-CEM cells, reduces the proportion of S-phase cells, and inhibits RNA synthesis^[1].</p> <p>Cytotoxic activities of Anticancer agent 201 against eight tumor (including multidrug resistant variants) and two normal fibroblast cell lines^[1]</p> <table border="1"> <thead> <tr> <th>Cell lines</th> <th>CCRF-CEM</th> <th>CEM-DNR</th> <th>K562</th> <th>K562-TAX</th> <th>A549</th> <th>HCT116</th> <th>HCT116p53 -/-</th> <th>U20S</th> <th>BJ</th> <th>MRC-5</th> </tr> </thead> <tbody> <tr> <td>IC₅₀ (μM)</td> <td>3.5</td> <td>4.9</td> <td>23</td> <td>17</td> <td>11</td> <td>10</td> <td>18</td> <td>19</td> <td>∞50</td> <td>27</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>CCRF-CEM cancer cell line</td> </tr> <tr> <td>Concentration:</td> <td>3.5 μM, 17.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24h</td> </tr> <tr> <td>Result:</td> <td>Induced the strongest cytotoxic reaction and the number of apoptotic cells increased significantly. Resulted in a significant decrease in mitochondrial membrane potential of CCRF-CEM cells in a dose-dependent manner.</td> </tr> </table>										Cell lines	CCRF-CEM	CEM-DNR	K562	K562-TAX	A549	HCT116	HCT116p53 -/-	U20S	BJ	MRC-5	IC ₅₀ (μM)	3.5	4.9	23	17	11	10	18	19	∞50	27	Cell Line:	CCRF-CEM cancer cell line	Concentration:	3.5 μM, 17.5 μM	Incubation Time:	24h	Result:	Induced the strongest cytotoxic reaction and the number of apoptotic cells increased significantly. Resulted in a significant decrease in mitochondrial membrane potential of CCRF-CEM cells in a dose-dependent manner.
Cell lines	CCRF-CEM	CEM-DNR	K562	K562-TAX	A549	HCT116	HCT116p53 -/-	U20S	BJ	MRC-5																														
IC ₅₀ (μM)	3.5	4.9	23	17	11	10	18	19	∞50	27																														
Cell Line:	CCRF-CEM cancer cell line																																							
Concentration:	3.5 μM, 17.5 μM																																							
Incubation Time:	24h																																							
Result:	Induced the strongest cytotoxic reaction and the number of apoptotic cells increased significantly. Resulted in a significant decrease in mitochondrial membrane potential of CCRF-CEM cells in a dose-dependent manner.																																							

Cell Cycle Analysis^[1]

Cell Line:	CCRF-CEM cancer cell line
Concentration:	3.5 μ M, 17.5 μ M
Incubation Time:	24h
Result:	Caused the cell cycle to be blocked or slowed down in the G0/G1 phase, while the proportion of S phase cells decreases. At 17.5 μ M, the mitosis rate of the cells decreased. At 3.5 μ M increased the proportion of BRDU-positive cells. At 17.5 μ M, the proportion of BRDU-positive cells decreased. At 17.5 μ M, RNA synthesis almost completely stopped.

Western Blot Analysis^[1]

Cell Line:	CCRF-CEM cancer cell line
Concentration:	3.5 μ M, 17.5 μ M
Incubation Time:	24h
Result:	Leaded to decreased expression of both Bcl-2 and Bcl-XL. At 17.5 μ M, caused the activation of caspase-3 and the cleavage of PARP.

REFERENCES

[1]. Kazakova A, et al. Novel triterpenoid pyrones, phthalimides and phthalates are selectively cytotoxic in CCRF-CEM cancer cells - Synthesis, potency, and mitochondrial mechanism of action. Eur J Med Chem. 2024;269:116336.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA